CEACAM5 Mouse Monoclonal Antibody [Clone ID: CEA-Y2]
CAT#: AM09248PU-N
CEACAM5 mouse monoclonal antibody, clone CEA-Y2, Aff - Purified
Conjugation: HRP
Need it in bulk or conjugated?
Get a free quote
CNY 6,120.00
货期*
4周
规格
Product images
Specifications
Product Data | |
Clone Name | CEA-Y2 |
Applications | ELISA, WB |
Recommend Dilution | ELISA: The antibody can be used in sandwich ELISA for detection of CEA in combination with matched capture antibody Clone CEA-Y1 (Cat.-No AM09247PU-N). Western Blot: 25 ng/lane of antigen can be detected when the antibody was used at 100 ng/ml. |
Reactivity | Human |
Host | Mouse |
Clonality | Monoclonal |
Immunogen | Human Carcinoembryonic Antigen (CEA). |
Specificity | Recognizes Carcinoembryonic Antigen CEA. Cross-reactivity with other Human protein was not found. |
Formulation | 0.01M PBS, pH 7.0 State: Aff - Purified State: Lyophilized purified IgG fraction |
Reconstitution Method | Restore with Double distilled water to adjust the final concentration to 1.0 mg/ml. |
Purification | Affinity Chromatography on Protein G |
Conjugation | Unconjugated |
Storage Condition | Upon receipt, store (in aliquots) at -20°C. Avoid repeated freezing and thawing. |
Gene Name | carcinoembryonic antigen related cell adhesion molecule 5 |
Database Link | |
Background | Carcinoembryonic Antigen (CEA) is a 180-200 KD glycoprotein expressed at high level in the epithelial cells of the embryonic colon. The expression is stopped after birth. CEA serum content is low in normal population and only slightly elevated in heavy smokers. Increased serum CEA level was found to be associated with colorectal carcinoma, gastric carcinoma, pancreatic carcinoma, lung carcinoma, and breast carcinoma. However elevated CEA level does not necessarily indicate neoplastic conditions. CEA level is useful for monitoring tumour recurrence after surgical resection of carcinoma. |
Synonyms | CEA, Carcinoembryonic antigen |
Reference Data |
Documents
Product Manuals |
FAQs |
SDS |
Resources
抗体相关资料 |
其它CEACAM5产品
Customer
Reviews
Loading...